CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Bristol-Myers Squibb Company

BMY
$126.59BLarge Cap

Next catalyst

PDUFAMay 13, 2027in 177 days

mezigdomide

relapsed or refractory multiple myeloma (RRMM), in combination with carfilzomib and dexamethasone (MeziKd)

Get an email about BMY's next catalysts

Track Bristol-Myers Squibb Company (BMY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 20 more upcoming events in our data (Phase 2 readout, Phase 3 readout, company event).See the timeline

Catalyst Timeline

22 upcoming, 3 past

Phase 2

Elotuzumab Phase 2 Est. Readout

December 2026~Elotuzumab52

Estimated primary completion for Elotuzumab trial (NCT02718833) in Multiple Myeloma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Nivolumab Phase 2 Est. Readout

December 2026~Nivolumab60

Estimated primary completion for Nivolumab trial (NCT04413123) in Papillary Renal Cell Carcinoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Ipilimumab Phase 2 Est. Readout

December 2026~Ipilimumab100

Estimated primary completion for Ipilimumab trial (NCT03333616) in Genitourinary Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

Nivolumab in Phase 2 Est. Readout

December 2026~Nivolumab in112

Estimated primary completion for Nivolumab in trial (NCT05492123) in Uterine Cervical Neoplasms. Topline data typically follows completion by weeks to months.

Source
Phase 3

Phase 3 Results - Cobenfy

December 2026~

For Alzheimer's psychosis. Bristol Myers has extended the ADEPT-2 Phase 3 trial of Cobenfy for Alzheimer's psychosis due to irregularities, pushing the expected data readout from end of 2025 to sometime in 2026.

Other

Other

Jan 1, 2027

Bristol Myers Squibb will merge its separate research and development departments into a single unified R&D entity, effective 1 January 2027.

Source
Phase 2

Nivolumab Phase 2 Est. Readout

January 2027~Nivolumab39

Estimated primary completion for Nivolumab trial (NCT03465592) in Sarcoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Nivolumab Phase 2 Est. Readout

February 2027~Nivolumab76

Estimated primary completion for Nivolumab trial (NCT06946797) in Non-Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.

Source

Upcoming FDA decisions

How BMY's past catalysts played out

Market Overview

Stock performance and key metrics

NYSEPharmaceutical PreparationsPharmaceuticals🇺🇸North AmericaPRINCETON32.5K employees

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.

Website
Drug Pipeline

Milvexian

Phase 3

Ischemic Stroke; Ischemic Attack, Transient

KarXT

Phase 3

Bipolar-I Disorder With Mania or Mania With Mixed Features

Deucravacitinib

Phase 3

Plaque Psoriasis

Vinflunine

Phase 3

Bladder Cancer

Abatacept

Phase 3

Nephrotic Syndrome

Belatacept

Phase 3

Kidney Transplantation

mavacamten

Phase 3

Hypertrophic Cardiomyopathy

stavudine extended-release, lamivudine, efavirenz

Phase 3

HIV Infections

LPV/r +2 NRTIs (Delayed/optional Switch Group)

Phase 3

HIV Infections

Pomalidomide

Phase 3

Multiple Myeloma

vinflunine and best supportive care

Phase 3

Transitional Cell Carcinoma of the Urothelial Tract

paclitaxel (PTX)

Phase 3

Breast Cancer

BMS-986504

Phase 3

Pancreatic Ductal Adenocarcinoma

Ipilimumab

Phase 3

Prostatic Neoplasms, Castration-Resistant

BMS-986393

Phase 3

Relapsed or Refractory Multiple Myeloma (RRMM)

Pegylated interferon alfa-2a (pegIFNα-2a)

Phase 3

Hepatitis C Virus (HCV)

Nivolumab

Phase 3

Recurrent Head and Neck Squamous Cell Carcinoma

Pumitamig

Phase 3

Untreated, Unresectable, or Metastatic Colorectal Cancer

BMS-650032 (Asunaprevir)

Phase 3

Hepatitis C

BMS-790052 (Daclatasvir)

Phase 3

Hepatitis C

Entecavir (ETV)

Phase 3

Hepatitis B

Relatlimab

Phase 3

Lymphoma, Non-Hodgkin

BMS-936558 (Nivolumab)

Phase 3

Melanoma

Entecavir

Phase 3

Chronic Hepatitis B

Lopinavir+ritonavir

Phase 3

HIV Infections

Peginterferon Lambda-1a

Phase 3

Hepatitis C Virus

NKTR-214

Phase 3

Melanoma

Irbesartan/HCTZ

Phase 3

Hypertension

Cetuximab/Erbitux

Phase 3

Head and Neck Cancer

MDX-1379 (gp100) Melanoma Peptide Vaccine

Phase 3

Melanoma

HBI-8000 in combination with nivolumab

Phase 3

Unresectable or Metastatic Melanoma

Intravenous (IV) abatacept

Phase 3

Rheumatoid Arthritis

Apixaban

Phase 3

Deep-Vein Thrombosis

Megestrol acetate

Phase 3

Anorexia

Iza-bren

Phase 3

Non-Small Cell Lung Cancer

DCV/ASV/BMS-791325

Phase 3

Hepatitis C

Lenalidomide

Phase 3

Lymphoma

adefovir

Phase 3

Hepatitis B

Lamivudine (3TC)

Phase 3

HIV Infections

Daclatasvir

Phase 3

Hepatitis C

Efavirenz (EFV)

Phase 3

HIV Infections

Belatacept More Intensive Regimen (MI)

Phase 3

Renal Transplantation

Xanomeline and Trospium Chloride Capsules

Phase 3

Schizophrenia

BMS-791325

Phase 3

Chronic Hepatitis C

Indinavir (IDV)

Phase 3

HIV Infections

peg-interferon alfa-2a

Phase 3

Hepatitis C Virus

Indinavir sulfate

Phase 3

HIV Infections

Elotuzumab (BMS-901608; HuLuc63)

Phase 3

Smoldering Multiple Myeloma

Repotrectinib

Phase 3

Carcinoma, Non-Small-Cell Lung

Sofosbuvir

Phase 3

Hepatitis C

peginterferon alfa-2a

Phase 3

Hepatitis C Virus

Ritonavir (NRV)

Phase 3

HIV Infections

Tanespimycin

Phase 3

Multiple Myeloma

Apremilast

Phase 3

Psoriasis

BMS-986489 (BMS-986012+Nivolumab)

Phase 3

Extensive-Stage Small Cell Lung Cancer

SAR302503

Phase 3

Hematopoietic Neoplasm

Belatacept Less Intensive Regimen (LI)

Phase 3

Renal Transplantation

Entecavir + Tenofovir

Phase 3

Hepatitis B, Chronic

Asunaprevir

Phase 3

Hepatitis C Virus Infection

BMS-986205

Phase 3

Advanced Cancer

Muraglitazar

Phase 3

Diabetes Mellitus

KarX-EC

Phase 3

Alzheimer Disease

metformin HCl

Phase 3

Diabetes Mellitus, Non-Insulin-Dependent

brivanib

Phase 3

Advanced Non-small Cell Lung Cancer

Anti-Tumor Necrosing Factor (TNF) Therapy

Phase 3

Rheumatoid Arthritis

BMS-986278

Phase 3

Pulmonary Fibrosis

oral antibiotics

Phase 3

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have

Nivolumab/rHuPH20

Phase 3

Melanoma

Stavudine

Phase 3

AIDS Dementia Complex

Ozanimod

Phase 3

Colitis, Ulcerative

Topical Dapsone

Phase 3

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have

Tegafur-gimeracil-oteracil potassium

Phase 3

Gastric Cancer

Nivolumab and rHuPH20

Phase 3

Clear Cell Renal Cell Carcinoma

Irbesartan

Phase 3

Congestive Heart Failure

BMS-986165

Phase 3

Ulcerative Colitis

Subcutaneous (SC) abatacept

Phase 3

Rheumatoid Arthritis

ipilimumab (MDX-010, BMS-734016)

Phase 2

Melanoma

Cobimetinib

Phase 2

Advanced or Metastatic Solid Tumors

BMS-582949

Phase 2

Rheumatoid Arthritis, NOS

Lirilumab

Phase 2

CANCER,NOS

BMS-986036

Phase 2

Hepatic Cirrhosis

MDX-1100

Phase 2

Ulcerative Colitis

Nivolumab (BMS-936558)

Phase 2

Melanoma

relatlimab+nivolumab

Phase 2

Melanoma

Cabazitaxel

Phase 2

Metastatic Prostate Neuroendocrine Carcinoma

Ixabepilone

Phase 2

Breast Cancer

Nivolumab + Relatlimab

Phase 2

Melanoma Stage III

Ipilimumab Injection

Phase 2

Prostate Cancer Metastatic

Nitroglycerin (NTG)

Phase 2

Heart Failure

irinotecan + Carboplatin + erbitux

Phase 2

Metastatic Breast Cancer

Nivolumab and Ipilimumab Combination for Prostate Cancer

Phase 2

Advanced Metastatic Cancer

Branebrutinib

Phase 2

Dermatitis, Atopic

Fianlimab

Phase 2

Prostate Cancer

Nivolumab and Ipilimumab and Combination for Metastatic Cancer

Phase 2

Advanced Metastatic Cancer

Nivolumab Combined with Anlotinib

Phase 2

NSCLC Stage IV

Procarbazine

Phase 2

Lymphoma

Navlimetostat

Phase 2

Solid Tumors

Nivolumab plus Relatlimab

Phase 2

Squamous Cell Carcinoma of the Skin

Corticosteroid: Prednisolone

Phase 2

Melanoma

Corticosteroid: Triamcinolone

Phase 2

Melanoma

Ribasphere

Phase 2

Hepatitis C

Nivolumab and surgical resection

Phase 2

Head and Neck Squamous Cell Carcinoma

Relatlimab and nivolumab fixed dose combination (FDC)

Phase 2

Stage II Melanoma

BMS-936558-01

Phase 2

Cervical Cancer

Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab

Phase 2

Melanoma

Nivolumab Injection

Phase 2

Recurrent and/or Metastatic Platinum-refractory SCCHN

Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

Phase 2

Melanoma

Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab

Phase 2

Melanoma

GVAX

Phase 2

Previously Treated Metastatic Adenocarcinoma of the Pancreas

Calcium folinate

Phase 2

Lymphoma

Dose Expansion Doublet: Combination of NKTR-214 + nivolumab

Phase 2

Melanoma

Relatlimab (BMS-986016)

Phase 2

Colon Carcinoma

Liso-cel

Phase 2

Lymphoma

Solu-medrol

Phase 2

Leukemia

atazanavir + ritonavir + dolutegravir

Phase 2

HIV-1 Infection

Relatlimab FDC + Nivolumab

Phase 2

Metastatic Triple-negative Breast Cancer

Corticosteroid: Dexamethasone

Phase 2

Melanoma

Corticosteroid: Hydrocortisone

Phase 2

Melanoma

Nivolumab plus Ipilimumab

Phase 2

Bladder Cancer

Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)

Phase 2

Lymphoma, Non-Hodgkin

Chemotherapy, carboplatin

Phase 2

Glioblastoma

Arlocabtagene Autoleucel

Phase 2

Multiple Myeloma

Corticosteroid: Methylprednisolone

Phase 2

Melanoma

Corticosteroid: Prednisone

Phase 2

Melanoma

Nivolumab Intravenous

Phase 2

Melanoma (Skin)

combination nivolumab and ipilimumab

Phase 2

Carcinoma, Non-Small-Cell Lung

Corticosteroid: Fludrocortisone

Phase 2

Melanoma

Corticosteroid: Meprednisone

Phase 2

Melanoma

INX-08189 Fasted

Phase 2

Hepatitis C

Ipilimumab in

Phase 2

Localized Oesogastric Adenocarcimona

INX-08189

Phase 2

Hepatitis C

Darbeopoetin

Phase 2

MDS (Myelodysplastic Syndrome)

INX-08189 with low-fat meal

Phase 2

Hepatitis C

BMS-986165 Dose B

Phase 2

Active Psoriatic Arthritis

Fedratinib

Phase 2

Myelofibrosis

APX005M

Phase 2

Metastatic Pancreatic Adenocarcinoma

Ipilimumab and nivolumab

Phase 2

Cutaneous Melanoma

Nivolumab and relatlimab

Phase 2

Cutaneous Melanoma

Izalontamab Brengitecan

Phase 2

Carcinoma, Non-Small-Cell Lung

Ipilimumab Nivolumab and relatlimab

Phase 2

Cutaneous Melanoma

Ipilimumab+ Budesonide

Phase 2

Malignant Melanoma

Ipilimumab/Nivolumab

Phase 2

Metastatic Renal Cell Carcinoma

CC-97540

Phase 2

Lupus Erythematosus, Systemic

MDX-010/MDX-010 + Docetaxel

Phase 2

Prostate Cancer

Drugs Nivolumab

Phase 2

Renal Cell Carcinoma, Clear Cell

BMS-986213 (Relatlimab-Nivolumab FDC)

Phase 2

Renal Cell Carcinoma, Clear Cell

Nivolumab, Surgery, Radiotherapy

Phase 2

Squamous Cell Carcinoma of the Oral Cavity

SOX

Phase 2

Gastric Cancer

Relatlimab + Nivolumab

Phase 2

Melanoma

Nivolumab, Surgery, Chemoradiotherapy

Phase 2

Squamous Cell Carcinoma of the Oral Cavity

cabiralizumab

Phase 2

Peripheral T Cell Lymphoma

BMS-650032 (NS3 Protease Inhibitor)

Phase 2

Hepatitis C

Combination of varlilumab and nivolumab

Phase 2

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Nivolumab & Ipilimumab

Phase 2

Prostate Cancer

Galunisertib

Phase 2

Solid Tumor

Pegylated Interferon Lambda (pegIFNλ)

Phase 2

Hepatitis C

PegIFN lambda

Phase 2

Hepatitis B Virus

CCR2/CCR5 dual antagonist

Phase 2

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

5-Fluorouracil (infusional)

Phase 2

Colorectal Cancer (CRC)

CT-322

Phase 2

Colorectal Cancer (CRC)

Nivolumab Monotherapy

Phase 2

Advanced Metastatic Cancer

Ipilimumab, Melphalan and Dactinomycin

Phase 2

Melanoma

Nivolumab/Ipilimumab

Phase 2

Carcinoma, Renal Cell

COM701 in combination with BMS-986207 and nivolumab

Phase 2

Endometrial Neoplasms

Nivolumab/Relatlimab in a fixed dose combination

Phase 2

Cutaneous Squamous Cell Carcinoma

Nivolumab + Ipilimumab

Phase 2

Colorectal Cancer Metastatic

Sorivudine

Phase 2

HIV Infections

BNT327 Dose Level 1 (DL1)

Phase 2

Locally Advanced Breast Cancer

Tetanus vaccine

Phase 2

Advanced Cancer

BMS-986253

Phase 2

Prostate Cancer

DPV-001 vaccine

Phase 2

Advanced Cancer

Combination immunotherapy with Ipilimumab and Nivolumab

Phase 2

Small Cell Lung Cancer

Albumin-bound paclitaxel

Phase 2

Untreated Metastatic Pancreatic Ductal Adenocarcinoma

KRAS vaccine

Phase 2

Pancreatic Ductal Adenocarcinoma

BMS-936558

Phase 2

Hematologic Neoplasms

Adriamycine

Phase 2

Breast Cancer

Neoadjuvant nivolumab

Phase 2

Renal Cell Carcinoma

Dasatinib (BMS-354825)

Phase 2

Acute Myeloid Leukemia

Neoadjuvant relatlimab

Phase 2

Renal Cell Carcinoma

water pill daily

Phase 2

Atherosclerosis

Administration of BMS-986368

Phase 2

Post-Stroke Spasticity

Neoadjuvant ipilimumab

Phase 2

Renal Cell Carcinoma

BMS-813160

Phase 2

Colorectal Cancer

BMS-650032

Phase 2

Chronic Hepatitis C

MDX-010

Phase 2

Prostate Cancer

BMS-986177

Phase 2

Acute Ischemic Stroke

BMS-790052

Phase 2

Hepatitis C Infection

BMS-986178

Phase 2

Advanced Cancer

MDX-060

Phase 2

Hodgkin's Disease

BMS-986213

Phase 2

Gastric Cancer

BMS-770767

Phase 2

Dyslipidemia

Elotuzumab

Phase 2

Multiple Myeloma

Tyrosinase/gp100/MART-1 Peptides

Phase 2

Intraocular Melanoma

Trametinib

Phase 2

Colorectal Cancer

CTLA4Ig/Abatacept

Phase 2

Psoriasis Vulgaris

BMS-931699

Phase 2

Lupus

BMS-741672

Phase 2

Neuropathic Pain

BMS-690514

Phase 2

Breast Cancer

Ticagrelor

Phase 2

Coronary Artery Disease

Oral Azacitidine

Phase 2

Acute Myeloid Leukemia

HNO Donor

Phase 2

Heart Failure

BMS-986207

Phase 2

Non-Small Cell Lung Cancer

BMS-986166

Phase 2

Dermatitis, Atopic

BMS-823778

Phase 2

Diabetes Mellitus, Type 2

Pexacerfont

Phase 2

Major Depressive Disorder

BMS-986016

Phase 2

Hematologic Neoplasms

Platinum Doublet Chemotherapy

Phase 2

Non-Small-Cell Lung Cancer

BMS-986408

Phase 2

Advanced Solid Tumors

Anti-IP-10 Antibody

Phase 2

Colitis, Ulcerative

BMS-986179

Phase 2

Malignant Solid Tumor

Luspatercept

Phase 2

Anemia

BMS-817399

Phase 2

Rheumatoid Arthritis

BMS-954561

Phase 2

Post-Herpetic Neuralgia (PHN)

Nivolumab in

Phase 2

Uterine Cervical Neoplasms

antithymocyte globulin (rabbit)

Phase 2

Living-Donor Kidney Transplant

rHuPH20

Phase 2

Neoplasms by Site

BMS-986158

Phase 2

Advanced Tumors

Frequently asked questions

What is in Bristol-Myers Squibb Company's drug pipeline?→

CatalystAlert tracks 217 drug candidates in Bristol-Myers Squibb Company's (BMY) pipeline across Phase 3, Phase 2. Its lead program is Nivolumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Bristol-Myers Squibb Company's next FDA catalyst?→

Bristol-Myers Squibb Company's (BMY) next tracked catalyst is a PDUFA date expected May 13, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BMY biotech catalysts?→

Add BMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bristol-Myers Squibb Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply